The overall survival and progression-free survival (PFS) rates after 5 years for ALK+ ALCL undergoing CHOP treatment are over 70% and 60%, respectively, with 30–40% patients experiencing relapse [1]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.